Dihexa: What the Evidence Actually Shows

Dihexa is marketed as a nootropic and neuroregenerative peptide — sold as oral drops, framed as a synaptogenesis breakthrough for cognitive enhancement and Alzheimer's. Checking its actual research trail directly against PubMed's own record turns up something the marketing copy does not mention: one of the two foundational papers behind Dihexa's central scientific claim was formally retracted in 2025, after a university investigation found specific figures contained fabricated data.

What Dihexa actually is

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small-molecule analog of angiotensin IV (AngIV), a peptide fragment of the brain's renin-angiotensin system that had shown procognitive effects in rodents but was, in its natural form, poorly absorbed and unable to cross the blood-brain barrier. Researchers at Washington State University's Wright/Harding laboratory set out to chemically modify AngIV-derived tripeptides to fix exactly that problem. Their own 2013 paper states the result plainly: they "yielded an orally active, blood-barrier permeant, metabolically stabilized analog... (dihexa)"¹ — an orally bioavailable compound was the entire design goal, not an injectable one.

The central claim — and the retraction, verified directly

The compound's core scientific story is that Dihexa's procognitive, synapse-building ("synaptogenic") effects work through activation of the brain's hepatocyte growth factor (HGF)/c-Met receptor system — a specific mechanistic claim made in a 2014 follow-up paper from the same lab². That 2014 paper is the one this article's own live PubMed check confirms was formally retracted. A direct query against PubMed's "Retracted Publication" filter for "dihexa" returns exactly one result: this paper. The retraction notice, published April 29, 2025 — read in full via its PMC mirror for this article — states without hedging: "This article has been retracted at the request of the Editor. Following an investigation by Washington State University, Figures 1B, 2A/C, and data in the subsequent erratum submission for the article have been found to contain falsified and/or fabricated data and Leen H. Kawas and Joseph W. Harding were found to be solely responsible³." That is not a vague image-quality concern or an unresolved dispute — it is a named finding, following an institutional investigation, of fabricated data in the paper that supplied Dihexa's core mechanistic claim. The paper had already carried a formal Expression of Concern since September 2021, nearly four years before the retraction became final.

A second foundational paper — a different, still-unresolved status

Dihexa's actual discovery paper — the 2013 paper reporting its synthesis and oral bioavailability, quoted above — is a separate publication from the retracted one, and its status is different and worth being precise about: it also received a 2021 Expression of Concern, independently confirmed live for this article against PubMed's own record¹, but as of this article's publication it has NOT been retracted. It remains under an open, unresolved Expression of Concern rather than a finalized retraction. This article reports both facts exactly as they stand rather than treating "under review" and "retracted" as the same thing.

What the retraction does — and does not — mean

It's worth being precise about scope here rather than discarding the whole compound. The retraction concerns specific figures in one paper and the mechanistic claim they were used to support — that Dihexa's cognitive effects run through the HGF/c-Met system specifically. It is not evidence that Dihexa has zero biological activity in animals. A wholly independent 2021 study from China Pharmaceutical University — no shared authors with the Wright/Kawas/Harding lab — separately reported that Dihexa rescued cognitive impairment and restored memory in an APP/PS1 Alzheimer's-model mouse, but proposed a different pathway entirely (PI3K/AKT signaling, with anti-inflammatory effects on astrocytes and microglia), not the retracted paper's HGF/c-Met mechanism⁴. Read that combination honestly: the specific mechanistic claim in the retracted paper should not be treated as established science, while a real, independently-replicated, differently-explained rodent cognitive effect exists alongside it. Neither fact cancels the other out.

Zero human data — confirmed two independent ways

Whatever is happening in mice, none of it has been tested in a human being. A live PubMed search for "dihexa" returns 18 total results, read in full for this article — every one of them rat or mouse pharmacology, cell-culture work, or a review of that same animal literature. Zero human studies exist. FDA's own regulatory record independently corroborates the same conclusion, from a completely different angle: Dihexa acetate was at some point nominated to FDA for 503A compounding-bulk-substance consideration, and that nomination was later withdrawn — but FDA's own safety note on the withdrawn nomination, fetched live for this article, states directly: "FDA has not identified any human exposure data on drug products containing dihexa acetate administered via any route of administration. FDA lacks important information regarding any safety issues raised by dihexa acetate, including whether it would cause harm if administered to humans⁵." Two independent sources — a PubMed literature search and FDA's own regulatory file — reach the identical conclusion: nobody has published any record of Dihexa being given to a human, at any dose, by any route. ClinicalTrials.gov returns zero registered Dihexa studies, and openFDA's FAERS adverse-event database returns zero reports for "DIHEXA," confirmed live⁶ — a null result that reflects an absent evidence base rather than a demonstrated safety record.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell Dihexa — this site's own identity-layer research confirms it is not tagged to any reviewed seller. The honest evidence picture here is unusually layered for this site's corpus: a real design achievement (an orally active, BBB-penetrant AngIV analog), a foundational mechanistic paper formally retracted in 2025 for fabricated data with named individuals held responsible, a second foundational paper still under an unresolved Expression of Concern, an independent 2021 replication of a cognitive effect through a different proposed pathway, and zero human data of any kind — confirmed independently by both a literature search and FDA's own file. If you're researching compounds in a similar cognitive/neurotrophic space, our Semax evidence review covers a different compound with a genuinely longer human research history, including at least one real (if methodologically limited) human trial — a meaningfully different evidence position than Dihexa's current zero.